Alan Tan, MD, Vanderbilt University Medical Center, shares key insights from the TALAPRO-2 trial, discussing the overall survival benefit of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.
He explores the synergy between PARP inhibitors and ARSIs, the role of HRR testing in patient selection, and how liquid biopsies may improve treatment personalization. Dr. Tan also examines the impact of this combination on treatment sequencing, toxicity management, and evolving therapeutic strategies, including chemotherapy, PSMA-targeted therapies, and emerging clinical trials.